Table 3.
Baseline (n) | P | 25 weeks (n) | P | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IG | PG | Pre-T | IG | PG | 1 (a)-PT | |||||||||
PSQI | NP | MP | SP | NP | MP | SP | NP | MP | SP | NP | MP | SP | ||
PSQ | 0 | 12 | 31 | 2 | 13 | 26 | .064 | 0 | 10 | 33 | 5 | 18 | 18 | .043* |
SL | 2 | 6 | 35 | 2 | 7 | 32 | .948 | 0 | 22 | 21 | 1 | 12 | 28 | .064 |
SD | 1 | 12 | 30 | 2 | 5 | 34 | .059 | 0 | 19 | 24 | 0 | 10 | 31 | .042* |
HSE | 1 | 15 | 27 | 0 | 10 | 31 | .255 | 0 | 20 | 23 | 0 | 13 | 28 | .065 |
SDI | 0 | 17 | 26 | 3 | 14 | 24 | .191 | 0 | 27 | 16 | 4 | 10 | 27 | .040* |
DD | 0 | 34 | 9 | 0 | 31 | 10 | .592 | 3 | 35 | 5 | 0 | 29 | 12 | .065 |
Values are shown as n = number of patients with no problems, moderate problems, severe problems. PSQI, Pittsburgh sleep quality index; IG, intervention group; PG, placebo group; Pre-T, pre-therapeutic; 1 (a) PT, post-therapy (after 25 weeks of treatment); PSQ, Pittsburgh subjective quality; SL, sleep latency; SD, sleep duration; HSE, habitual sleep efficiency; SDI, sleep disturbance; DD, daily dysfunction; NP, no problems; MP, moderate problems; SP, severe problems. *P = .05 (95% CI).